CN1544005A - Traditional Chinese Medicine Mixture for Prevention and Treatment of Chicken Infectious Bursal Disease - Google Patents

Abstract

The invention is a traditional Chinese medicine mixture for preventing and treating chicken infectious bursal disease, which is named as Qilan Kangdu Decoction. The component medicines mainly include Radix Astragali, Radix Isatidis, Folium Folium, Rehmannia Radix, Radix Paeoniae Rubra, etc. The comparison test of the treatment of detoxification proved that among the six different treatment groups, the treatment group of this prescription had the best curative effect, the lightest pathological bleeding, and the most significant weight gain effect. It has been proved by the comparison test of virus challenge and prevention that whether this prescription is used alone or together with the vaccine, it can reduce the mortality rate and increase the level of specific antibodies; through the treatment verification of several groups of clinically ill chickens, the protection rate reaches about 90%. And it overcomes many disadvantages of other therapeutic drugs, has no toxic side effects and drug residues, and meets the requirements of green drugs and ensuring the safety of animal-sourced food. The drug has passed the review of new veterinary drugs in Jiangsu Province.

Description

Traditional Chinese Medicine Mixture for Prevention and Treatment of Chicken Infectious Bursal Disease

1. Technical field

The invention is a traditional Chinese medicine mixture for preventing and treating chicken infectious bursal disease, which is named as Qilan Kangdu Decoction, and belongs to a new type of Chinese veterinary medicine for preventing and treating chicken infectious bursal disease.

2. Technical Background

Chicken infectious bursal disease (Infectious bursal disease, IBD) has been a worldwide epidemic since it was first discovered in Gambro, Delaware, on the east coast of the United States in 1957. According to the survey, the seropositive rate of chicken flocks in the United States is almost 100%, about 90% in South America, 88% in the Netherlands, 76% in Italy, about 75% in Japan, and 61.5% in Germany. The disease was discovered in Guangzhou in my country in 1979. In 1980, Zhou Jiao and others isolated the IBD-CJ801 strain from imported chickens in Beijing, thus confirming the existence of the disease in my country.

IBD is an acute, highly contagious infectious disease that harms young chickens. Its greatest harm is to destroy the immune central organ of the chicken - the bursa of Fabricius, degeneration and necrosis of the B lymphocytes carrying the SIgM mark, resulting in severe and long-term immunosuppression, reducing the body's immune response to other vaccines, and reducing the immune response to other vaccines. Increased susceptibility to pathogens such as bacteria and viruses. Its onset is sudden, and it spreads rapidly. It usually begins to die on the third day of infection, reaches a peak in 5 to 7 days, and then subsides soon. The mortality rate of the disease is generally 15% to 50%, and the mortality rate of super-virulent infection can reach more than 70%. In recent years, some new features have appeared in the epidemic of IBD, which is manifested by the expansion of the age range of onset, from 3-day-old chicks to 180-day-old adult chickens, and the increase in atypical cases, mixed infections or syndromes, and those with high mortality may be up to 90%.

Because IBDV is relatively stable in the external environment, conventional disinfection and isolation measures can no longer control the disease. The main preventive measure is vaccination. In recent years, due to the emergence of super-strong IBDV and the differences in antigens among various serotypes and mutant strains, it is difficult to achieve ideal effects of vaccine immunization, and sometimes it will cause other diseases, causing huge economic losses to the chicken industry.

There is no specific western medicine treatment for IBD so far. Some people use dexamethasone and compound norethindrone for treatment, but they can only reduce the symptoms or relieve the condition, but cannot reduce the mortality rate. For early diseased chickens, the use of hyperimmune yolk antibody or hyperimmune serum has a certain effect, but both are easily affected by conditions such as preparation, storage and transportation, and the effect is unstable or there is a risk of spreading other diseases.

The preparation of hyperimmune yolk and serum comes from commercial chickens and eggs. Due to individual differences in immunized chickens or different antibody levels between batches, the antibody titer of the product is unstable. Both are high-protein substances, rich in nutrients, and are very easy to contaminate bacteria during the production process; they may also carry other pathogens, such as egg drop syndrome, avian leukosis, mycoplasma, etc., which pose a potential threat to the poultry industry. Yolk antibody contains a large amount of antigenic substances such as vitellin and fat, which can easily interfere with the immunity of sick chickens; the molecular weight of its protein and fat is very large, and intramuscular injection is not only difficult to absorb, but also causes local swelling, hemorrhage, necrosis, and even Causes stress and allergic reactions in the body. Antibodies are afraid of heat and must be stored and transported at low temperature. Especially in summer, they are easily spoiled and cannot be used. Therefore, it is imperative to find a new and more effective therapeutic drug from Chinese herbal medicine.

3. Contents of the invention

Technical Problems The present invention aims at the urgent need for green medicines in the prior art, and provides a pure traditional Chinese medicine preparation for preventing and treating chicken infectious bursal disease. Reach the purpose of reliable drug effect, no toxic and side effects, no drug residue, and food safety.

Technical solution A traditional Chinese medicine mixture for preventing and treating chicken infectious bursal disease, characterized in that,

The prescription amount of medicinal materials per 1000ml of medicinal liquid is: Astragalus 300g, Radix Radix 200g, Folium Folium 200g, Rehmannia 200g, Radix Paeoniae Rubra 100g.

The technological process for producing every 1000ml liquid medicine is: water extraction method. Add water to decoct the above five herbs twice, each time for 1 hour, filter, combine the filtrate, concentrate to 1000ml, add 4g of sodium benzoate, stir well, let it stand, filter or centrifuge, remove the precipitate, put it into sterile water for sterilization bottle.

Beneficial effect

From 2000 to 2001, under the support of the "Three Drugs Project" project of Jiangsu Province, the laboratory carried out research on new preparations of traditional Chinese medicine for chicken infectious bursal disease. Firstly, astragalus with strong anti-infectious bursal virus effect was selected by cell culture method as the main drug, and then three prescriptions were formulated according to the theory of traditional Chinese veterinary medicine and the pathology of chicken infectious bursal disease. Through repeated trials and comparisons, a prescription with the best effect was finally screened out and named as Qilan Kangdu Decoction.

The comparison test of the treatment of detoxification proved (Table 1~Table 3), the curative effect of Qilan Kangdu Decoction is better than the other two prescriptions, slightly better than egg yolk antibody, and the mortality rate of the drug treatment group is the lowest (18.97%), which is lower than that of egg yolk. The antibody control group (21.03%) was extremely significantly lower than the non-treated control group (46.7%); the positive rate of hemorrhage in sick chickens was the lightest, lighter than that of the egg yolk antibody control group, significantly (pectoral muscle, leg muscle) or extremely significant (spleen, Bursa of Fabricius) was lighter than that of the non-treated control group; the effect of weight gain was the most significant, the total weight gain and average weight gain were higher than that of the yolk antibody control group, and extremely significantly higher than that of the non-treatment control group. The challenge prevention test proved (Table 4-Table 9), whether this prescription is used alone or with the vaccine, it can reduce the mortality rate of sick chickens and increase the level of specific antibodies. Through the treatment verification of several groups of clinically ill chickens, the protection rate reaches about 90%.

Compared with the prior art, it also has the following advantages:

1. Western medicine has used dexamethasone and compound norethindrone for treatment, but they can only alleviate symptoms or alleviate the condition, but cannot reduce mortality. For early diseased chickens, the use of hyperimmune yolk antibody or hyperimmune serum has a certain curative effect, but both are easily affected by conditions such as preparation, storage and transportation, resulting in unstable effects or the risk of spreading other diseases, and the injection is troublesome. It is also easy to cause the stress response of sick chickens. The medicine is made of pure traditional Chinese medicine, has remarkable efficacy, is safe and reliable, and can overcome the above drawbacks.

2. According to the theory of traditional Chinese veterinary medicine, the medicine is made of astragalus for invigorating qi plus traditional Chinese medicine for clearing heat and detoxification, cooling blood and nourishing yin, promoting blood circulation and removing blood stasis. Modern pharmacological research shows that astragalus can enhance immune function and improve the immune suppression of sick chickens. The active ingredient astragalus polysaccharide and the heat-clearing and detoxifying medicine in the prescription have antiviral effects, the Yin-nourishing medicine can improve the dehydration state of sick chickens, the blood-activating and stasis-removing medicine can improve blood circulation, and reduce pathological bleeding. , the composition is novel and reasonable.

3. Most of the chicks refuse to eat and drink after the onset of the disease, while most of the other similar traditional Chinese medicines are powders, which are administered through the mixed feeding method. Not only the intake of the medicine cannot be guaranteed, but even after ingestion, there is also a process of digestion and absorption, which makes the medicine effective. It cannot be exerted in time; this medicine is an oral liquid dosage form prepared by extraction, and it is administered through the mixed drinking method, which can ensure the intake of the medicine and exert its curative effect as soon as possible.

4. The drug has no toxic side effects, no drug residue, meets the requirements of green drugs, and can guarantee the safety of animal source food; there are no three wastes in the production process, and no pollution to the environment.

The invention provides a pure traditional Chinese medicine preparation for preventing and treating chicken infectious bursal disease, which has passed the review of new veterinary drugs in Jiangsu Province and has reached the standards of innovation, science and practicability required in the patent.

4. Specific implementation

The prescription quantity of Qilan Kangdu Decoction per 1000ml medicinal liquid is: Astragalus 300g, Radix Radix 200g, Folium Isatidis 200g, Rehmannia 200g, Radix Paeoniae Rubra 100g.

The technological process for producing every 1000ml liquid medicine is: water extraction method. Add water to decoct the above five herbs twice, each time for 1 hour, filter, combine the filtrate, concentrate to 1000ml, add 4g of sodium benzoate, stir well, let it stand, filter or centrifuge, remove the precipitate, put it into sterile water for sterilization bottle.

(1) Efficacy test of Qilan Kangdu Decoction

The comparison test of the present invention's anti-toxin treatment proves that, compared with the non-treatment control group, egg yolk antibody treatment control group and the other two prescription treatment groups, the prescription treatment group has the best curative effect, the lightest pathological bleeding, and the most significant weight gain effect. The comparison test of challenge and prevention proves that whether this formula is used alone or together with the vaccine, it can reduce the mortality rate and increase the level of specific antibodies; through the treatment verification of several groups of clinically sick chickens, the protection rate reaches about 90%.

1. Qilan Kangdu Decoction Therapeutic Experiment

Test method 4 batches of experiments shared 1043 21-day-old non-immune Roman egg roosters (provided by Nanjing Tangquan Chicken Farm). The feeding was observed for 48 hours before the experiment, and 35 feather wing veins were randomly drawn for each batch of experiments to collect blood. After the IBDV maternal antibody was detected negative by agar diffusion method, they were randomly divided into 7 groups. The 7th group, 104 birds, were reared in isolation without any treatment; the remaining 6 groups (see Table 1 for the number of chickens) were weighed respectively to calculate the average weight; After 24 hours, the chicken flocks were treated with medicine when they showed typical symptoms of IBD such as listlessness, hair piles, watery diarrhea, and sporadic death.

Groups I～III, the traditional Chinese medicine experimental group, drink and take formula 1, formula 2, and formula 3 (Qilan Kangdu drink) sequentially; group IV, the single-drug main drug control group, drink and take astragalus, and the dose of the above four groups is 1ml per feather, administered once a day, for 3 consecutive days; group V, yolk antibody control group, pectoral muscle injection of yolk antibody 1ml/feather, once; group VI, no treatment control group.

Observation indicators and data processing (1) Mortality rate: the number of deaths in each group was recorded every day, and the mortality rate was calculated when the death stopped on the 7th day after the challenge. (2) Positive rate of organ hemorrhage: the dead chickens were autopsied one by one, and the percentage of hemorrhage in pectoralis muscle, leg muscle, spleen and bursa of Fabricius accounted for the dead was counted. (3) Weight gain: After the chickens stopped dying and basically recovered clinically, the total body weight of the surviving chickens in each group was weighed, and the total weight gain and average weight gain per bird were calculated. The data of the above three indicators were tested by t test for the difference between each group and the control group without treatment.

Test results (1) Mortality rate (Table 1): Group 3 was the lowest, followed by Group 1, Group 2, egg yolk antibody, and single main drug group. All groups had significant differences (P<0.05) ) or extremely significant (P<0.01) difference. The difference between the prescription 3 group and the untreated control group was the most significant (P<0.005), greater than that of the egg yolk antibody group. It shows that Qilan Kangdu Decoction has the best curative effect, slightly better than egg yolk antibody, and the effect of compound formula is better than that of single main medicine.

(2) Positive rate of hemorrhage in dead chicken organs (Table 2): still the lowest in group 3, pectoral muscle, leg muscle, spleen and bursa of Fabricius hemorrhage accounted for the percentages of the dead respectively: 15.70%; 42.66%; 22.15%; 50.51 %, significantly (P<0.05, pectoral muscle, leg muscle) or extremely significant (P<0.01, spleen, bursa of Fabricius) difference with the control group without treatment. It shows that prescription 3 can significantly reduce the hemorrhage of tissues and organs of sick chickens, and the effect is better than yolk antibody, single main medicine and other compound prescriptions.

(3) Changes in weight gain (Table 3): the total weight gain was the highest in group 3, with a total weight gain of 4.9 kg and an average weight gain of 75.5 g, followed by the single main drug control group, all of which were significantly higher than those in the no-treatment control group ( P<0.001); the total weight gain of other groups was negative. The average weight gain was still the highest in the prescription 3 group, followed by the single main medicine group, which was significantly higher than that in the control group without treatment (P<0.001). It shows that the output rate of square 3 is the highest, and the economic benefit is better.

2. Prevention test of Qilan Kangdu Decoction

Test method 222 29-day-old non-immune Romain egg cocks were randomly divided into 5 groups. Group I, Chinese medicine (Qilan Kangdu Decoction) group, 37 pigeons; Group II, vaccine group, 38 pigeons; Group III, Chinese medicine plus vaccine group 1, 38 pigeons; Group IV, Chinese medicine plus vaccine group 2, 41 pigeons; V group, virus-positive control group, 40 birds; another blank control group of 28 birds was kept in isolation, and was used to observe whether there were other infectious disease infections and the ratio of normal cysts.

Each group was observed and weighed after 48 hours of feeding, and the detection method of IBDV maternal antibody was the same as that of Experiment 1. Groups II-IV were immunized with eye drops and nasal drops; Groups III were given traditional Chinese medicine on the day of vaccine immunization; After 14 days (45 days old) brush the anus to challenge the virus, with an average of 0.2ml per feather; on the day of the challenge and 7, 14, 21, 28, 35 days after the challenge, 10 feathers were randomly selected from each group to collect blood to monitor the antibody titer.

Observation indicators and data processing (1) Mortality rate and autopsy changes: observation records are the same as experiment 1. (2) Weight gain rate: The body weight of the surviving chickens was weighed on the 35th day after challenge, and the total weight gain rate of each group was calculated. The above data were tested by t test to compare the significance of the differences between each treatment group and the virus positive control group, the traditional Chinese medicine prevention group and the vaccine group. (3) Serum IBDV antibody titer monitoring method: use AGP method. (4) Bursal index: when dead chickens were autopsyed, the body weight was weighed with a balance at the same time, and the bursa of Fabricius was separated and weighed. And from the blank control group, 3 chickens were randomly selected to weigh their body weight and bursa of Fabricius. Sac index and BBIX were then calculated according to the literature. The calculation formula is as follows: B/W (bursal index) = bursa weight (g) ÷ body weight (g) × 1000; BBIX = test group bursa index ÷ blank control group bursa index. If BBIX is less than 0.7, it is judged as bursa atrophy.

Test results (1) Mortality rate: The mortality rate of group I which used traditional Chinese medicine alone was the lowest, which was significantly different from that of the vaccine group and virus positive control group (P<0.05=; the mortality rate of groups III and IV of Chinese medicine plus vaccine was also lower than The vaccine group shows that Qilan Kangdu Decoction has the effect of preventing IBDV, and the protection rate of combined application with vaccine is also better than that of vaccine alone (Table 4).

(2) Positive rate of hemorrhage in dead chicken organs: Compared with the vaccine group, the leg muscle hemorrhage in the Chinese medicine group alone and the Chinese medicine plus vaccine 1 group was significantly (P<0.05) reduced; the bursa hemorrhage in the Chinese medicine group was extremely significant (P<0.05) 0.01) decrease. Show that Qilan Kangdu decoction can significantly reduce the hemorrhage of leg muscles and bursa of sick chickens (Table 5).

(3) Changes in weight gain: the order of change in total weight gain was Group IV > Group I > Group III > Group II > Group V. The first three groups were significantly higher than those in Group II and Group V (P<0.01). It shows that Qilan Kangdu Decoction alone or in combination with the vaccine can significantly increase the rate of weight gain and obtain better economic benefits (Table 6).

(4) Changes in capsule index: 48 hours after the challenge, the BBIX of the Chinese medicine group and the Chinese medicine plus vaccine group 2 were higher than 0.7, and the BBIX of each group was lower than 0.7 at the rest of the time. The bursa of Fabricius was in atrophic state in the vaccine group, the traditional Chinese medicine plus vaccine group 1 at 48h-120h, and the traditional Chinese medicine plus vaccine group 2 at 72h-144h. It was suggested that only the Chinese medicine group and the Chinese medicine plus vaccine 2 group administered 4 days before the challenge could resist bursa atrophy within 48 hours and reduce the damage caused by the virus (Table 7).

It can also be seen from the results that, except the traditional Chinese medicine plus vaccine group 2, the BBIX of the other 3 groups at 120 hours was higher than that at 96 hours, indicating that the damage of the bursa of Fabricius had begun to recover, and the Qilan Kangdu Decoction plus vaccine group 1 increased The magnitude is the largest, indicating that the recovery of the bursa injury is the fastest.

(5) Antibody changes: ① Antibody positive rate: on the 7th day after the challenge, the Chinese medicine group was the highest at 90%, the vaccine group was 62.5%, and the Chinese medicine plus vaccine 1 group and the Chinese medicine plus vaccine 2 group were 87.5%; Except for the 2 groups of traditional Chinese medicine plus vaccine, the remaining 3 groups were all 100% (Table 8).

② Antibody level: The Chinese medicine group was the highest on the 7th day after challenge, 1 titer higher than the vaccine group, and the Chinese medicine plus vaccine 1 group and Chinese medicine plus vaccine 2 group were 0.88 titer higher than the vaccine group. The traditional Chinese medicine plus vaccine group 1 reached the peak at 21 days after the challenge, while the other 4 groups reached the peak at 28 days after the challenge; on the 35th day after the challenge, the antibody levels of each group began to decline, and the Chinese medicine control group had the fastest decline (Table 9). The above results showed that the antibody response in the Qilan Kangdu Decoction group was fast, and the serum antibody reached a higher level in the shortest time.

(2) Regional verification

In Yangji Town, Guanyun County, a total of 6 groups of more than 5,000 chicks aged 15 to 30 days developed the disease, all of which had typical symptoms of chicken infectious bursal disease. The necropsy was diagnosed as chicken infectious bursal disease. After anti-drug decoction treatment, the protection rate was about 90%.

(3) Summary of the efficacy of Qilan Kangdu Decoction

The comparison test of the treatment of detoxification proved that among the six different treatment groups, the Qilan Kangdu Decoction treatment group had the best curative effect, the lightest pathological bleeding, and the most significant effect on weight gain. The challenge prevention test proves that whether this prescription is used alone or together with the vaccine, it can reduce the mortality rate and increase the level of specific antibodies; through the treatment verification of several groups of clinically ill chickens, the protection rate reaches about 90%.

                                                                                     

Group

index

I I II II III III IV IV VI

Number of samples 117 100 195 118 195 199

Deaths 23 20 37 33 41 93

Mortality rate (%) 19.67±5.51 ^B※ 20.00±0 ^B 18.97±3.31 ^C 27.97±7.78 ^A 21.03±8.96 ^B 46.70±5.84

Note: Compared with the non-treatment group, A, P<0.05; B, P<0.01; C, P<0.005; D, P<0.001. The following 2 tables are the same.

             Table 2. Positive rate of organ hemorrhage in each group of dead chickens in the challenge treatment experiment (%)

Group

organ

I I II II III III IV VI

Pectoral muscle 26.45±28.80 33.64±3.71 15.70 ^A ±6.64 30.24±8.10 44.64±22.94 42.78±13.31

Leg muscles 86.36±17.37 90.46±0.32 42.66 ^A ±7.96 75.76±24.31 83.33±23.57 75.60±22.87

Spleen 81.82±21.43 62.73±16.72 22.15 ^B ±11.39 60.66±34.31 62.08±16.68 55.60±29.55

Bursa 86.36±24.74 76.27±10.93 50.51 ^B ±3.99 84.85±5.95 73.69±10.41 82.75±15.66

                                                                                            

group

index

I I II II III III IV IV V VI

Total weight before treatment (kg) 19.41 20.73 37.03 19.46 36.34 36.86

Total weight after treatment (kg) 18.70 20.23 41.93 20.01 35.42 24.31

Total weight gain (kg) -0.71±0.70 ^C -0.50±0.07 ^C 4.9±2.03 ^D 0.55±0.63 ^D -0.92±1.40 ^C -12.55±1.90

Average weight before treatment (g) 165.9 207.3 189.9 164.9 186.3 185.2

Average weight after treatment (g) 198.9 252.8 265.4 235.4 230.0 229.3

Average weight gain (g) 33.0±36.3 45.5±21.2 75.5±57.1 ^B 70.5±1.6 ^A 43.7±20.5 44.1±14.3

           Table 4. Number of deaths and mortality rate (%) in each group of the challenge prevention experiment

Group

index

I I II II III III IV IV V

Sample size 37 38 38 41 40

Deaths 11 17 13 15 19

Mortality 22.81 ^Aa 44.74 34.21 36.59 47.50

Note: ① Compared with the virus positive control group, A, P<0.05; B, P<0.01; C, P<0.005; D, P<0.001.

②Compared with the vaccine group, a, P<0.05; b, P<0.01; c, P<0.05; d, P<0.001. The same below.

               Table 5. Positive rate of organ hemorrhage in each group of dead chickens in the challenge prevention experiment (%)

Group

organ

I I II II III III IV IV V

Chest 32.00 36.36 23.33 33.33 45.16

Leg muscles 60.00 ^A 84.85 56.67 ^A 75.76 70.97

Spleen 56.00 54.55 76.67 63.64 58.06

Bursa 56.00 ^Bb 87.88 83.33 90.91 83.87

                                   Table 6. Body weight and total weight gain before and after administration of each group in the challenge prevention experiment

Indicators Groups

I II II III III IV V

Total weight before administration (kg) 11.73 12.30 11.85 12.25 11.85

Total weight after administration (kg) 51.95 43.26 50.63 58.83 41.35

Total weight gain (kg) 40.22 30.96 38.78 46.58 29.50

Total weight gain (%) 342.88 ^Bb 251.71 327.26 ^Bb 380.24 ^Bb 248.95

                                                                                      

index

Group Time after challenge (h)

                                                                                                                       

48 390.7±28.51 0.99±0.36 4.06 1.04

72 378.7±35.40 0.91±0.19 2.40 0.51

I

96 321.6±28.61 0.88±0.17 2.74 0.48

120 310.5±0 0.70±0 2.25 0.50

48 390.1±48.74 0.84±0.17 2.15 0.61

72 384.5±35.36 0.85±0.28 2.20 0.47

II

96 388.1±22.71 1.07±0.22 2.75 0.48

                                                                                                         

48 389.8±27.93 0.65±0.20 1.67 0.47

72 372.8±50.46 0.88±0.19 2.36 0.50

III

96 337.3±16.56 0.70±0.10 2.08 0.36

                                                                                               

48 432.0±28.69 1.17±0.38 2.70 0.77

72 387.7±37.20 0.95±0.27 2.46 0.52

IV

                                                                                

96

                                                                                                        

                                                             

48 341.0±6.36 0.53±0.04 1.55 0.44

72 348.1±65.64 0.78±0.24 2.24 0.47

V

96 356.9±39.94 0.82±0.14 2.28 0.40

                                                                                                                 

48 436.7±70.53 1.63±0.51 3.52 -

72 487.0±100.80 2.30±0.36 4.72 -

96 529.2±46.46 3.03±0.90 5.73 -

negative control group

                                                           

...

                                                    

         Table 8 Changes in the positive rate of AGP antibodies in each group in the challenge prevention experiment (%)

Time after challenge (d)

group

7 14 21 28 35

I 90 100 100 100 100

II 62.5 100 100 100 100

III 87.5 100 100 100 100

IV 87.5 87.5 100 100 100

V 77.78 100 100 100 100

Table 9. Changes of antibody titers in each group in the challenge prevention experiment (log2)

Time after challenge (d)

group

7 14 21 28 35

I 2.50 8.50 9.70 10.7 8.56

II 1.50 8.20 8.80 11.00 10.80

III 2.38 8.50 10.13 9.75 9.00

IV 2.38 6.25 8.50 9.88 9.38

V 2.22 8.63 8.75 10.25 9.63

Claims (2)

1, a kind of herb mixture of preventing and treating infectious bursal disease is characterized in that,

The recipe quantity medical material of every 1000ml medicinal liquid is: Radix Astragali 300g, Radix Isatidis 200g, Folium Isatidis 200g, Radix Rehmanniae 200g, Radix Paeoniae Rubra 100g.

2. the described a kind of preparation method of preventing and treating the herb mixture of infectious bursal disease of claim 1 is characterized in that, with above five kinds of Chinese medicine, decoct with water twice, each 1 hour, filter merging filtrate, be concentrated into 1000ml, add 4 gram sodium benzoate, leave standstill filtration or centrifugal after stirring evenly, remove precipitation, the aseptic subpackaged bottle of going into to sterilize.